Qiagen N.V.
QGEN
Rang în acțiuni
#2058
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Preț acțiune
$48.85
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$10.07B
Schimbare (1 zi)
4.96%
Schimbare (1 an)
0.61%
Țară
NL
Tranzacționează Qiagen N.V. (QGEN)
Categorie
Healthcare
Raport P/E pentru Qiagen N.V. (QGEN)
Raport P/E la data de October 2026 TTM: 23.36
Conform celor mai recente rapoarte financiare și prețului acțiunilor Qiagen N.V., raportul P/E actual (TTM) este 23.36. La sfârșitul anului 2024, compania avea un P/E de 118.59.
Istoricul raportului P/E pentru Qiagen N.V. din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 23.36 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 118.59 | 304.12% |
| 2023 | 29.34 | 6.39% |
| 2022 | 27.58 | 8.47% |
| 2021 | 25.43 | -26.45% |
| 2020 | 34.57 | -118.18% |
| 2019 | -190.18 | -539.51% |
| 2018 | 43.27 | -76.64% |
| 2017 | 185.20 | 113.69% |
| 2016 | 86.66 | 65.09% |
| 2015 | 52.50 | 5.85% |
| 2014 | 49.60 | -41.99% |
| 2013 | 85.50 | 145.24% |
| 2012 | 34.86 | -2.40% |
| 2011 | 35.72 | 6.66% |
| 2010 | 33.49 | -5.84% |
| 2009 | 35.57 | -13.60% |
| 2008 | 41.17 | -45.13% |
| 2007 | 75.02 | 120.64% |
| 2006 | 34.00 | 14.85% |
| 2005 | 29.60 | -15.34% |
| 2004 | 34.97 | -18.98% |
| 2003 | 43.16 | 25.46% |
| 2002 | 34.40 | -57.92% |
| 2001 | 81.75 | -67.43% |
| 2000 | 250.99 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 36.15 | 54.74% |
US
|
|
| 39.77 | 70.23% |
US
|
|
| -290.26 | -1,342.32% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 46.31% |
US
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.